Celldex's Phase 1 Study of CDX-1401 Published in Science Translational Medicine

By: via Benzinga
Celldex Therapeutics, Inc. (Nasdaq: CLDX) announced today that final data from its Phase 1 study of CDX-1401 in solid tumors, including ...
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.